C Arndt

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma
    C Arndt
    Department of Pediatrics and Adolescent Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Med Pediatr Oncol 32:93-6. 1999
  2. pmc Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803
    Carola A S Arndt
    Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 27:5182-8. 2009
  3. ncbi request reprint Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group
    Carola A S Arndt
    Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Pediatr Blood Cancer 50:33-6. 2008
  4. ncbi request reprint Significance of persistent mature rhabdomyoblasts in bladder/prostate rhabdomyosarcoma: Results from IRS IV
    Carola A S Arndt
    Department of Pediatrics and Adolescent Medicine, Mayo Medical School, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Pediatr Hematol Oncol 28:563-7. 2006
  5. pmc Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group
    Carola A S Arndt
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 16:4024-30. 2010
  6. ncbi request reprint Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide
    C Arndt
    Department of Pediatric Hematology Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:1894-901. 2004
  7. ncbi request reprint Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from intergroup rhabdomyosarcoma study iv
    Carola Arndt
    Mayo Clinic, Rochester, Minnesota, Duke University Medical Center, Durham, North Carolina, USA
    J Urol 171:2396-403. 2004
  8. ncbi request reprint Fas expression in lung metastasis from osteosarcoma patients
    Nancy Gordon
    Division of Pediatrics, Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, and Division of Pediatrics Hematology Oncology, Mayo Clinic, Rochester, MN, USA
    J Pediatr Hematol Oncol 27:611-5. 2005
  9. ncbi request reprint Rothmund-Thomson syndrome due to RECQ4 helicase mutations: report and clinical and molecular comparisons with Bloom syndrome and Werner syndrome
    N M Lindor
    Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Med Genet 90:223-8. 2000
  10. ncbi request reprint Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator
    Mark R Litzow
    Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 43:2099-107. 2002

Detail Information

Publications23

  1. ncbi request reprint Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma
    C Arndt
    Department of Pediatrics and Adolescent Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Med Pediatr Oncol 32:93-6. 1999
    ....
  2. pmc Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803
    Carola A S Arndt
    Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 27:5182-8. 2009
    ....
  3. ncbi request reprint Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group
    Carola A S Arndt
    Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Pediatr Blood Cancer 50:33-6. 2008
    ..Treatment with alternating cycles of non-cross-resistant chemotherapy has been used in a number of diseases with good results...
  4. ncbi request reprint Significance of persistent mature rhabdomyoblasts in bladder/prostate rhabdomyosarcoma: Results from IRS IV
    Carola A S Arndt
    Department of Pediatrics and Adolescent Medicine, Mayo Medical School, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Pediatr Hematol Oncol 28:563-7. 2006
    ..Sequential biopsies are subject to sampling error and should only be performed in the context of protocol-directed therapy to avoid unnecessary radical surgeries...
  5. pmc Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group
    Carola A S Arndt
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 16:4024-30. 2010
    ....
  6. ncbi request reprint Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide
    C Arndt
    Department of Pediatric Hematology Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:1894-901. 2004
    ..To evaluate the spectrum of and determine the risk factors for the development of liver toxicity (hepatopathy) after therapy with vincristine, dactinomycin, and cyclophosphamide (VAC) for rhabdomyosarcoma in children and adolescents...
  7. ncbi request reprint Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from intergroup rhabdomyosarcoma study iv
    Carola Arndt
    Mayo Clinic, Rochester, Minnesota, Duke University Medical Center, Durham, North Carolina, USA
    J Urol 171:2396-403. 2004
    ....
  8. ncbi request reprint Fas expression in lung metastasis from osteosarcoma patients
    Nancy Gordon
    Division of Pediatrics, Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, and Division of Pediatrics Hematology Oncology, Mayo Clinic, Rochester, MN, USA
    J Pediatr Hematol Oncol 27:611-5. 2005
    ..0013). These data indicate that loss of Fas may be one mechanism by which OS cells evade host resistance in the lung. Chemotherapy may induce regression by upregulating Fas...
  9. ncbi request reprint Rothmund-Thomson syndrome due to RECQ4 helicase mutations: report and clinical and molecular comparisons with Bloom syndrome and Werner syndrome
    N M Lindor
    Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Med Genet 90:223-8. 2000
    ..These three disorders all manifest abnormal growth, premature aging, and predisposition to site-specific malignancies. The clinical and molecular aspects of RTS, Bloom syndrome, and Werner syndrome are compared and contrasted...
  10. ncbi request reprint Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator
    Mark R Litzow
    Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 43:2099-107. 2002
    ..01) and maximum blood urea level (P = 0.03). Ten patients (all with creatinine levels > or = 150 micromol/l) were treated with tissue plasminogen activator; only two had a significant response and only one survived beyond day 120...
  11. ncbi request reprint Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia
    Vilmarie Rodriguez
    Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 47:1583-92. 2006
    ..Thus, in adolescents and adults, 153Sm-EDTMP may provide a relatively simple and effective means for using irradiation to eliminate AML within the marrow...
  12. ncbi request reprint Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut
    Vilmarie Rodriguez
    Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Pediatr Blood Cancer 49:212-5. 2007
    ..In case 2, corticosteroid-unresponsive grade 3 acute liver and gut GVHD developed on day +37. In both patients, GVHD responded to the infliximab-daclizumab regimen without toxicity and immunosuppressive therapy was discontinued...
  13. ncbi request reprint Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia
    Vilmarie Rodriguez
    Division of Pediatric Hematology Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Pediatr Transplant 9:122-6. 2005
    ..She achieved engraftment on day +23. Three years after transplantation, she continues to have complete remission. Samarium and melphalan constitute a well-tolerated regimen with potential antileukemic activity...
  14. ncbi request reprint High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases
    Peter M Anderson
    Department of Pediatrics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 20:189-96. 2002
    ..Because the dose-limiting toxicity of (153)Sm-EDTMP is thrombocytopenia, a dose-escalation trial using peripheral-blood progenitor cells (PBPCs) or marrow support was conducted to treat metastatic bone cancer...
  15. ncbi request reprint Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer
    Ravi D Rao
    Department of Medical Oncology, Mayo Clinic, 200, 2nd Street SW, Rochester, Minnesota 55905, USA
    Am J Clin Oncol 26:493-8. 2003
    ..In one patient, we have evidence of upregulation of melanoma-specific cytotoxic T-cells. Further study is warranted to understand the impact of this therapy on the natural history of metastatic cancer...
  16. ncbi request reprint Diagnosis and management of bone malignancy in adolescence
    Jonathan S C Caudill
    Division of Pediatric Hematology Oncology, Department of Pediatrics, Mayo Clinic, 200 First Street SW, Rochester, MN 55901, USA
    Adolesc Med State Art Rev 18:62-78, ix. 2007
    ..Survivorship issues in children and adolescents treated for these malignancies are discussed...
  17. ncbi request reprint Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient
    Ashley W Jensen
    Department of Radiation Oncology, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Pediatr Hematol Oncol 29:156-9. 2007
    ..Platelet counts were well controlled after 16 months of follow-up, and no further thrombotic events occurred. Mucositis was the main adverse effect of treatment...
  18. ncbi request reprint Intraabdominal desmoplastic small round cell tumors: a diagnostic and therapeutic challenge
    Imran Hassan
    Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 104:1264-70. 2005
    ..To the authors' knowledge, only limited data are available on the natural history and optimal treatment of this disease...
  19. ncbi request reprint Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood
    James G Douglas
    Department of Radiation Oncology, University of Washington Affiliated Hospitals, Seattle, WA, United States
    Eur J Cancer 43:1045-50. 2007
    ..To evaluate the local control rates and survival rates of patients with Group III parameningeal rhabdomyosarcoma (PM-RMS) treated with a dose intensive chemotherapy regimen followed by irradiation...
  20. ncbi request reprint Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy
    Douglas S Hawkins
    Department of Pediatrics, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
    Cancer 98:2447-56. 2003
    ..The goal of the current study was to define the clinical features and outcome of recurrent osteosarcoma (OS) in children and young adults initially treated with contemporary chemotherapy...
  21. ncbi request reprint Alveolar soft-part sarcoma responsive to intensive chemotherapy
    H James Nickerson
    Department of Pediatrics, Marshfield Clinic, WI 54449, USA
    J Pediatr Hematol Oncol 26:233-5. 2004
    ..Following intensive multiagent chemotherapy, pulmonary metastases showed in vivo evidence of tumor death. The patient has remained disease-free for 10 years following treatment...
  22. doi request reprint The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the Children's Oncology Group
    Andrea Hayes-Jordan
    University of Texas MD Anderson Cancer Center, Box 87, Houston, TX 77030, USA
    J Pediatr Surg 43:831-6. 2008
    ..Chest wall RMS is a site in which the limitations of surgical excision are realized. We aim to determine the impact of surgical excision in chest wall RMS...
  23. ncbi request reprint Intrathecal mafosfamide: a preclinical pharmacology and phase I trial
    Susan M Blaney
    Texas Children s Cancer Center, 6621 Fannin St, CC 1410 00, Houston, TX 77030 2399, USA
    J Clin Oncol 23:1555-63. 2005
    ..A phase I and pharmacokinetic study of IT mafosfamide was performed to determine a dose for subsequent phase II trials...